GlassScriptPhysician profile
Mika Cole
NPI 1285688168
$9,918.64
in general payments reported to CMS, 2019-2025
30 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,972 · 2020: $959 · 2021: $809 · 2022: $2,106 · 2023: $1,509 · 2024: $1,070 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,697 · Honoraria: $350 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,697.45 |
| Honoraria | $350.00 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,391.26 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,699.10 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Alk-Abello, INC | $571.11 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $538.94 | 2022-2024 | |
| Amgen INC. | $530.91 | 2019-2022 | |
| Genzyme Corporation | $440.80 | 2022-2025 | |
| Pfizer INC. | $344.10 | 2019-2023 | |
| Antares Pharma, INC. | $342.10 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $320.95 | 2019-2025 | |
| Grifols USA, LLC | $301.55 | 2022-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $273.83 | 2022-2025 | Cuvitru, Hyqvia, Takhzyro |
| Shire North American Group INC | $247.07 | 2019 | |
| Blueprint Medicines Corporation | $235.22 | 2022-2025 | Ayvakit |
| Abbvie INC. | $202.55 | 2019 | |
| Sunovion Pharmaceuticals INC. | $194.20 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $155.61 | 2020-2023 | Hizentra, Haegarda |
| Ars Pharmaceuticals Operations, INC. | $149.26 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $126.97 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Incyte Corporation | $125.00 | 2022 | |
| Mylan Specialty L.P. | $124.99 | 2024 | Yupelri |
| Lilly USA, LLC | $118.26 | 2025 | Ebglyss |
| Kaleo, INC. | $100.43 | 2023 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.26 | 2020-2021 | |
| Ionis Pharmaceuticals, INC. | $41.67 | 2025 | Dawnzera |
| Pharming Healthcare, INC. | $39.68 | 2022-2025 | Ruconest |
| Janssen Biotech, INC. | $33.91 | 2019 | |
| Octapharma USA, INC. | $33.64 | 2022 | |
| Aurinia Pharma U.S., INC. | $21.64 | 2021 | |
| Circassia INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mika Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.